This section of the global Janssen website provides a company overview in several languages. It is not targeted to any specific audience or country. Enter the can you have psoriatic arthritis and ankylosing spondylitis you wish to search for. Collaborating in more than 150 countries.
By clicking on a link below, you may enter a different part of this website, or a website outside of Janssen. These sections or websites are governed by their own Legal and Privacy Policies. In the study for the treatment of active PsA, patients experienced improvement in joint symptoms and inhibition of structural damage. In the study for treatment of active AS, results showed improvement in measures of disease activity. There is a need for new treatment options for patients with psoriatic arthritis.
Professor of Medicine, University of California San Diego, and Chair of the GO-VIBRANT steering committee. The approval of IV golimumab for the treatment of active psoriatic arthritis brings an important new treatment option to patients, especially those who prefer IV administration, and offers one with a 30-minute infusion time. PsA and AS are based on two large-scale, pivotal Phase 3 studies involving more than 600 patients. ACR20 and ASAS20 are standard measures used to assess clinical improvement in PsA and AS, respectively.
Science University in Portland, and Chair of the GO-ALIVE steering committee. The GO-ALIVE Phase 3 study demonstrated the efficacy of IV golimumab in reducing the signs and symptoms of disease, as well as improving physical function and quality of life in patients. Vice President of Medical Affairs at Janssen Scientific Affairs, LLC. We know having all three indications is valuable to rheumatologists and for patients who prefer to have their treatment administered by their healthcare provider. MTX during the double-blind phase.
The primary endpoint was ACR20 response at week 14. The study continued through 60 weeks. The primary endpoint was ASAS20 response at week 16. It is estimated that at least one million Americans are living with PsA, and up to 30 percent of patients living with psoriasis can develop PsA.
The disease causes pain, stiffness and swelling in and around the joints and commonly appears between the ages of 30 and 50, but can develop at any time. Though the exact cause of PsA is unknown, genes, the immune system and environmental factors are all believed to play a role in the onset of the disease. AS frequently also causes enthesitis, which is inflammation where ligaments and muscles attach to bones, most commonly those within the spine. It is the primary disease in a group of arthritis-related diseases known as spondyloarthritis. It is estimated that 700,000 people in the U.
The disease affects men more often than women and typically manifests in early adulthood. In contrast to mechanical low back pain, low back pain and stiffness with AS worsen after a period of rest or upon waking up in the morning and improve after exercise, a hot bath or a shower. TNF-alpha monoclonal antibody that targets both soluble and transmembrane bioactive forms of human TNF-alpha, a protein that when overproduced in the body due to chronic inflammatory diseases can cause inflammation. 30-minute infusion for the treatment of adult patients with moderately to severely active RA used in combination with MTX, active PsA or active AS.
22 countries, including the U. Some of these infections have been fatal. Tell your doctor if you have been in close contact with people with TB. Tell your doctor if you are prone to or have a history of infections or have diabetes, HIV or a weak immune system. Hepatosplenic T-cell lymphoma, a rare and fatal lymphoma, has occurred mostly in teenage or young adult males with Crohn’s disease or ulcerative colitis who were taking a TNF blocker with azathioprine or 6-mercaptopurine.
You should tell your doctor if you have had or develop lymphoma or other cancers. Your doctor should periodically examine your skin, especially if you have a history of skin cancer. TNF blocker, or if you are scheduled to or recently received a vaccine. Some of these cases have been fatal. Your doctor will closely monitor you if you have heart failure. Tell your doctor right away if you get new or worsening symptoms of heart failure like shortness of breath, swelling of your lower legs or feet, or sudden weight gain.
Tell your doctor right away if you have symptoms like vision changes, weakness in your arms or legs, or numbness or tingling in any part of your body. Rarely, people using TNF blockers have developed lupus-like symptoms. Tell your doctor if you have any symptoms such as a rash on your cheeks or other parts of the body, sensitivity to the sun, new joint or muscle pain, becoming very tired, chest pain or shortness of breath, swelling of the feet, ankles or legs. Contact your doctor immediately if you develop symptoms such as feeling very tired, skin or eyes look yellow, poor appetite or vomiting, or pain on the right side of your stomach.
If this occurs, your body may not make enough blood cells to help fight infections or help stop bleeding. Your doctor will check your blood counts before and during treatment. Tell your doctor if you have signs such as fever, bruising, bleeding easily, or paleness. Some reactions can be serious and life-threatening.